Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy

Vascular endothelial growth factor (VEGF) performs as an angiogenic and permeability factor in ovarian cancer, and its overexpression has been associated with poor prognosis. However, models to study its role as a marker of tumor progression are lacking. We generated xenograft variants derived from the A2780 human ovarian carcinoma (1A9), stably transfected with VEGF121 in sense (1A9-VS-1) and antisense orientation (1A9-VAS-3). 1A9, 1A9-VS-1, and 1A9-VAS-3 disseminated in the peritoneal cavity of nude mice, but only 1A9-VS-1, the VEGF121-overexpressing tumor variant, produced ascites. Tumor biopsies from 1A9-VS-1 showed alterations in the vascular pattern and caused an angiogenic response in the chorioallantoic membrane assay. A significant level of soluble VEGF was detectable in the plasma of mice bearing 1A9-VS-1 even at an early stage of tumor growth. Plasma VEGF correlated positively with tumor burden in the peritoneal cavity and ascites accumulation. Cisplatin reduced the tumor burden and ascites in mice bearing 1A9-VS-1; the response was associated with a significant decrease of VEGF in plasma. This 1A9-VS-1 xenograft model reproduces the behavior of human ovarian cancer by growing in the peritoneal cavity, being highly malignant, and producing ascites. Plasma VEGF as a marker of tumor progression offers a valuable means of detecting early tumor response and following up treatments in an animal model.

[1]  R. Labianca,et al.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. , 2003, European journal of cancer.

[2]  R. Ozols,et al.  Focus on epithelial ovarian cancer. , 2004, Cancer cell.

[3]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Gasparini,et al.  Prognostic value of vascular endothelial growth factor in breast cancer. , 2000, The oncologist.

[5]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[6]  J. Cherrington,et al.  The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  N. Ferrara.  Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.

[8]  C. Bucana,et al.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. , 1998, Journal of the National Cancer Institute.

[9]  G. Viglietto,et al.  Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene , 1999, Oncogene.

[10]  Marina Ziche,et al.  Cell-Mediated Delivery of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor onto the Chick Chorioallantoic Membrane: Endothelial Fenestration and Angiogenesis , 2001, Journal of Vascular Research.

[11]  F. B. Sørensen,et al.  Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[12]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[13]  M. Parmar,et al.  International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. , 2003, Journal of the National Cancer Institute.

[14]  Edison T Liu,et al.  Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. , 2004, Molecular cancer therapeutics.

[15]  R. Giavazzi,et al.  Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. , 1998, The American journal of pathology.

[16]  Jin-Yi Jiang,et al.  Changes of Messenger RNA Expression of Angiogenic Factors and Related Receptors During Follicular Development in Gilts1 , 2002, Biology of reproduction.

[17]  S. Ozalp,et al.  Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. , 2003, European journal of gynaecological oncology.

[18]  H. Dvorak,et al.  Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. , 2003, The American journal of pathology.

[19]  Anil K Sood,et al.  Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  P. V. van Diest,et al.  Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. , 2002, The American journal of pathology.

[21]  J. Beckstead,et al.  A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  E. Manseau,et al.  Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis , 2002, The Journal of experimental medicine.

[23]  J. Wood,et al.  Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. , 2000, International journal of oncology.

[24]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[25]  H. Keizer,et al.  Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[27]  J. Beckstead.  A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues: addendum. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  B. Teicher,et al.  LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice , 2004, Cancer Chemotherapy and Pharmacology.

[29]  A. Heerschap,et al.  Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. , 2003, Cancer research.

[30]  C. Garlanda,et al.  Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. , 1994, European journal of cell biology.

[31]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[32]  A Vacca,et al.  New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. , 1997, Journal of vascular research.

[33]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[34]  H. Augustin,et al.  Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[35]  A. Harris,et al.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: Is the current literature meaningful? , 2004, Clinical & Experimental Metastasis.

[36]  Christopher C W Hughes,et al.  VEGF121 and VEGF165 Regulate Blood Vessel Diameter Through Vascular Endothelial Growth Factor Receptor 2 in an in vitro Angiogenesis Model , 2003, Laboratory Investigation.

[37]  D. Eberhard,et al.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.

[38]  P. Allavena,et al.  Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.

[39]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[40]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Sauer,et al.  Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. , 2001, The Journal of clinical endocrinology and metabolism.

[42]  L. Kedes,et al.  Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. , 2000, Journal of the American College of Cardiology.

[43]  J. Folkman,et al.  Avascular and vascular phases of tumour growth in the chick embryo. , 1977, British Journal of Cancer.

[44]  R. Einspanier,et al.  Expression and Tissue Concentration of Vascular Endothelial Growth Factor, Its Receptors, and Localization in the Bovine Corpus Luteum During Estrous Cycle and Pregnancy1 , 2000, Biology of reproduction.

[45]  R. Giavazzi,et al.  Copyright © American Society for Investigative Pathology Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis , 2022 .

[46]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[47]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[48]  R. Kerbel,et al.  Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. , 2002, Cancer research.

[49]  C. N. Lee,et al.  Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. , 1999, Gynecologic oncology.